spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Healthcare Industry News:  Famotidine 

Biopharmaceuticals Licensing

 News Release - January 9, 2009

Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB

Two Marketed CNS Products With U.S. Revenues of $20 Million Two FDA Approved but Unlaunched Products

DUBLIN, Ireland, January 9 -- (Healthcare Sales & Marketing Network) -- Azur Pharma Limited ("Azur Pharma") today announced that it licensed the exclusive U.S. marketing rights for Niravam® (alprazolam orally disintegrating tablets), Parcopa® (carbidopa-levodopa orally disintegrating tablets), Kemstro(TM) (baclofen orally disintegrating tablets) and Fluxid(TM) (Famotidine orally disintegrating tablets) from UCB (Euronext: UCB). Financial terms were not disclosed.

Niravam, Parcopa and Kemstro are central nervous system ("CNS") products. Azur Pharma's CNS business currently markets FazaClo® in the U.S. for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenia drug treatments. FazaClo is supplied as an innovative orally disintegrating tablet that uses proprietary formulation technologies licensed from CIMA Labs Inc. ("CIMA"), a subsidiary of Cephalon Inc (NASDAQ: CEPH ).

Mr Seamus Mulligan, Chairman and Chief Executive of Azur stated, "We are pleased to add these valuable products to our portfolio. In particular, Niravam, Parcopa and Kemstro represent a broadening of our CNS franchise and are consistent with our approach of improving our products through the application of value added drug delivery technologies."

Niravam and Parcopa have been commercially available in the U.S. since 2005 and 2004, respectively. There is one approved generic competitor to Parcopa. Two ANDAs to Niravam have been filed with the FDA. Kemstro and Fluxid are both FDA approved but not yet commercially available in the U.S.

About Azur Pharma

Azur is a privately held pharmaceutical company dedicated to enhancing patients' lives by developing and marketing pharmaceutical products in specialist therapeutic areas. Azur's strategy is to identify, evaluate, selectively acquire and enhance the value of late stage development and approved pharmaceutical products. (Website: http://www.azurpharma.com )

Source: Azur Pharma

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

Search: Azur Pharma 
Search: UCB 
Search: Niravam 
Search: Parcopa 
Search: Kemstro 
Search: Fluxid 
Healthcare Industry NewsFeed  


FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.